Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 27;370(13):1270-1.
doi: 10.1056/NEJMc1316118.

Thrombotic microangiopathy associated with interferon beta

David Hunt  1 , David Kavanagh, Iain Drummond, Belinda Weller, Chris Bellamy, James Overell, Stephen Evans, Andrew Jackson, Siddharthan Chandran
Affiliations

Thrombotic microangiopathy associated with interferon beta

David Hunt et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cases of Thrombotic Microangiopathy Associated with a Common Manufacturing Source of Interferon Beta
Shown are renal-biopsy specimens obtained from four patients receiving recombinant interferon beta therapy in South Scotland in whom thrombotic micro-angiopathy was diagnosed during an 18-month period (Panels A through D). All four specimens show arteriolar luminal obliteration with swollen endothelium and fibrin (arrows; hematoxylin and eosin and silver staining [Panels A, B, and D] and Martius scarlet blue [MSB] staining [Panel C]). All four patients were treated with recombinant interferon beta from the same manufacturer, as confirmed by tracing of drug batches. The Venn diagram shows the overlap of 10 batches prescribed to patients in the year before the presentation of the index case (Panel E).
See this image and copyright information in PMC

References

    1. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–504. - PubMed
    2. Lancet. 1999;353:678. Erratum.
    1. Recombinant interferon-beta: thrombotic microangiopathy [December 2013];Drug Safety Update. :S3. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON355481.
    1. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2009;15:219–28. - PubMed

Publication types

MeSH terms